Wolfe Research upgraded iRhythm to Outperform from Peer Perform with a $115 price target. With the company seen being on the cusp of meaningful improvements in margin and business model efficiency and the FDA overhang around Zio AT poised to lift this fall, the firm sees a “sensible entry valuation,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm Technologies Achieves Significant Operational Milestone with Launch of Initial Phase of Manufacturing Automation
- iRhythm launches initial phases of manufacturing automation plans
- iRhythm Technologies to Present at the 2024 Truist Securities MedTech Conference
- iRhythm Technologies to Present at the William Blair 44th Annual Growth Stock Conference
- iRhythm selling off on ‘essentially a non-issue,’ says Truist